In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amyris Inc.

www.amyris.com

Latest From Amyris Inc.

Appointments: GSK, Neurocrine Biosciences, Cue Biopharma, BenevolentAI And Ferring Pharmaceuticals

This week's roundup includes two executive appointments by GSK, plus updates from Radius Health Inc., Cue Biopharma and BenevolentAI, with Myovant Sciences making four key management hires.

Appointments BioPharmaceutical

Appointments: Gilead, Biogen, Nordic Nanovector, Neon Therapeutics, Achaogen and vasopharm

This week's roundup includes executive appointments by Gilead Sciences, Nordic Nanovector, Mereo BioPharma, vasopharm and Rigontec. Biogen has also appointed two executives to its planned spin-off company, Bioverativ.

Appointments

Synthetic Biology And The Computerization Of Drug Development

Synthetic biology offers opportunity across many industries, but the ultimate prize may be health care. The millions of dollars investors have poured into companies developing CAR-T cell therapies and gene editing technologies points to growing confidence in the power of gene manipulation to generate novel, approvable therapeutics, even if for now these are just the early steps toward creating fully synthetic organisms.

BioPharmaceutical Innovation

Deals Shaping The Medical Industry, March 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in February 2016.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
    • Nutraceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Amyris Biotechnologies Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Amyris Inc.
  • Senior Management
  • John G Melo, Pres. & CEO
    Jonathan Wolter, Interim CFO
    Kathleen Valiasek, CBO
    Joel Cherry, President, R&D
  • Contact Info
  • Amyris Inc.
    Phone: (510) 450-0761
    5885 Hollis St.
    Ste. 100
    Emeryville, CA 94608
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register